C11444: Novel Biomarker for Diagnosis of Gastric CancerNovelty:
The reported technology identifies a novel biomarker for clinical detection, inflammation severity, and disease progression in gastric cancer.
Value Proposition:
The technology outlined is a diagnostic technique to detect a biomarker known to play a major role in gastric carcinogenesis. The method is inexpensive and 25% more accurate in identifying gastric cancer adenocarciomas than clinical diagnosis. Other advantages of the technology include:
• Assessment of inflammation severity and disease progression.
• Classification of the endoscopic biopsies as high or low risk.
• Distinction between types of pre-malignant lesions.
• More effective personalized treatment options for patients.
Technical Details:
Researchers at the Johns Hopkins University provide evidence of a biomarker and an assay that can be used to diagnose the presence of gastric cancer adenocarcinomas and distinguish endoscopic biopsies as low or high risk. Specifically, researchers utilized an ELISA-based approach to quantify a biomarker index in a gastric cancer case-control study. Of the 209 patients diagnosed by endoscopy, pathologists confirmed that 50 cases had an adenocarcinoma and 159 cases were non-tumor controls. The results from the novel approach indicated that there is a significant differential in the biomarker expression as gastric lesions progress through the multistep carcinogenesis stages leading to gastric cancer.
Looking for Partners:
To develop and commercialize the technology as efficient and inexpensive diagnostic tool for detection of gastric cancer.
Stage of Development:
Pre-clinical
Data Availability:
Under CDA / NDA
Publications/Associated Cases:
Not available at this time
